about
Pharmacological properties of the Ca2+-release mechanism sensitive to NAADP in the sea urchin eggExtracellular nicotinamide phosphoribosyltransferase, a new cancer metabokineSperm deliver a new second messenger: NAADPNAADP mobilizes Ca(2+) from reserve granules, lysosome-related organelles, in sea urchin eggsStore-operated Ca2+ entry is remodelled and controls in vitro angiogenesis in endothelial progenitor cells isolated from tumoral patientsNAADP-induced Ca(2+ signaling in response to endothelin is via the receptor subtype B and requires the integrity of lipid rafts/caveolaeCalcium controls the transcription of its own transporters and channels in developing neurons.Expression of inositol trisphosphate receptors.Characterization of NAD uptake in mammalian cells.NAADP: an atypical Ca2+-release messenger?Triazine dyes are agonists of the NAADP receptor.How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009-2013.Calcineurin controls inositol 1,4,5-trisphosphate type 1 receptor expression in neurons.Medicinal chemistry of combretastatin A4: present and future directions.Click chemistry reactions in medicinal chemistry: applications of the 1,3-dipolar cycloaddition between azides and alkynes.Difficulties in the production of identical drug products from a pharmaceutical technology viewpoint.Searching for new animal models of Alzheimer's disease.Dasatinib: is it all in the dose?The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: a systematic review and meta-analysis.Triptan nonresponders: do they exist and who are they?Pharmacogenomics of episodic migraine: time has come for a step forward.Glial calcium signalling in Alzheimer's disease.Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review.Metabolic fate of combretastatin A-1: LC-DAD-MS/MS investigation and biological evaluation of its reactive metabolites.A concise synthesis of pyrazole analogues of combretastatin A1 as potent anti-tubulin agents.Identification of a sirtuin 3 inhibitor that displays selectivity over sirtuin 1 and 2.Identification of novel antitubulin agents by using a virtual screening approach based on a 7-point pharmacophore model of the tubulin colchi-site.Regioselective Suzuki coupling of dihaloheteroaromatic compounds as a rapid strategy to synthesize potent rigid combretastatin analogues.Reciprocal potentiation of the antitumoral activities of FK866, an inhibitor of nicotinamide phosphoribosyltransferase, and etoposide or cisplatin in neuroblastoma cells.NAADP links histamine H1 receptors to secretion of von Willebrand factor in human endothelial cells.Replacement of the double bond of antitubulin chalcones with triazoles and tetrazoles: Synthesis and biological evaluation.Activation of TRPV4 channels reduces migration of immortalized neuroendocrine cells.Multiple roles of protein kinase a in arachidonic acid-mediated Ca2+ entry and tumor-derived human endothelial cell migration.A novel potent nicotinamide phosphoribosyltransferase inhibitor synthesized via click chemistry.Synthesis, molecular docking and biological evaluation as HDAC inhibitors of cyclopeptide mimetics by a tandem three-component reaction and intramolecular [3+2] cycloaddition.Synthesis, biological evaluation, and molecular docking of Ugi products containing a zinc-chelating moiety as novel inhibitors of histone deacetylases.A concise entry into nonsymmetrical alkyl polyamines.Solution-phase parallel synthesis and biological evaluation of combretatriazoles.Triazole-modified histone deacetylase inhibitors as a rapid route to drug discovery.Synthesis and biological evaluation of isosteric analogues of FK866, an inhibitor of NAD salvage.
P50
Q24672945-258041A6-A383-40F3-8CBA-84D16B3C68FBQ28069876-303B0047-D211-47BF-850D-E8E7C23AC9EAQ28204936-7142C238-E049-487F-995B-F3A22E03C465Q28216586-AAA44806-28E6-4166-A006-5509F57DE233Q28484028-4FB3C66C-1204-48EF-B90C-BC615892346BQ28572693-CC14C967-6913-49C2-81D0-97034FFD89C5Q33797935-01BCD86C-6624-44C0-B227-0575FFAA159DQ33834374-549A6EC9-0515-4B95-8C42-A5C5FFB48D56Q34009257-2B92A432-2197-4619-9043-2BCBA21C0D27Q34586893-6F146BE7-9389-4BE3-BF12-A43372D30858Q35047514-720FB0AD-5940-4A57-AE7D-55D57B7347F3Q36034344-644A6F0F-6064-4652-B798-1EB235CB26F9Q36371071-2FF5D546-84B5-45FE-A418-523BD68781B3Q36488159-6E24F79E-411B-4635-A82B-11827CC843CAQ36925684-0E6F398D-7C16-41B5-AA4C-67A14A37A6D9Q37093853-40133B04-A1B0-4299-B7DB-3CE04140C2A3Q37616396-CEFF046D-6223-4E2F-BD6C-1E7589B1FCB2Q37707362-4C91385B-0AB1-41A0-A8D7-43C53FBE97CEQ38025588-780A1CB8-F00D-4CB1-9E26-C1190377809CQ38096945-5F71E9B6-B266-46C3-A03C-EE792EF57886Q38195629-E53203AC-2B6D-42FD-9F13-C1D85ACC9375Q38220737-E74CECA8-CA45-4C24-ADC9-910559EB27D2Q38222509-086209AD-EB84-46F3-9D53-BA4F2554DB99Q39179772-6EB8836B-7327-40C5-BD28-F174DFCD7CE0Q39189336-E9941F9A-050F-43E4-852B-308ABD8B3EE4Q39307719-34627077-408D-4737-9FBC-64E00DE7C9CCQ39450385-5605E99F-8DD1-4E52-BA5D-0543A6B8020AQ39520172-8B03AB76-941D-4262-BA26-CC7BB9DE425DQ39522057-4841C718-A443-486B-A4EB-93F8B478DBB3Q39583631-0D3873D0-46F9-4ACD-87F6-A43617683DECQ39618677-99DC3173-F9A4-4EF1-B0A2-7D80789253B0Q39618925-9DA3202F-ECBE-4D1B-87B1-C8DFAD9B3D69Q39651543-0AFA1972-4476-4DA1-B755-30183DC7E69AQ39766966-8221F584-A1F9-493E-8FD9-7970CF60E84EQ39846240-60297218-1107-4CED-9C98-04D05109FC48Q39864415-3A9B5A7C-76EA-4779-8A22-1EBA01774870Q39944577-B7429112-3395-415C-A152-09980E0462CFQ39953771-7E08B174-94E4-4614-AB3D-A48F6253BD17Q39965747-78C43A17-F3CC-4C15-84EF-BD897CD619F9Q40016907-77FBEA0B-6C12-4890-ABF7-B32FD5BDFC7B
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Armando A Genazzani
@nl
Armando A Genazzani
@sl
Armando A. Genazzani
@en
Armando A. Genazzani
@es
type
label
Armando A Genazzani
@nl
Armando A Genazzani
@sl
Armando A. Genazzani
@en
Armando A. Genazzani
@es
altLabel
armando a genazzani
@en
prefLabel
Armando A Genazzani
@nl
Armando A Genazzani
@sl
Armando A. Genazzani
@en
Armando A. Genazzani
@es
P106
P1153
56271730000
7202520320
P21
P31
P496
0000-0003-1923-7430